FDA Issues Some Concerns Regarding ARS Pharma's Investigational Allergy Treatment


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


The FDA released briefing documents ahead of the advisory committee for ARS Pharmaceuticals Inc's (NASDAQ:SPRY) neffy (ARS-1) for the emergency treatment of allergic reactions (type I), including anaphylaxis in adults and children,

The meeting is scheduled for Thursday, May 11.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Neffy is an intranasal epinephrine product.

Some of the key issues outlined in the briefing documents include:

The briefing documents note that epinephrine injection has been used since before 1938, and its effectiveness has never been evaluated.

As such, there is a paucity of data for epinephrine injection products, and the PK endpoints critical to establishing efficacy have not been determined. There is limited data on the ideal safe and effective dose beyond a generally accepted level of 0.01 mg/kg.

The briefing documents cite substantial variability in the PK profiles of epinephrine injection products used as comparators in the clinical studies of ARS-1 despite being administered by the same route, raising questions about which of the approved products should be used as the comparator and which PK endpoints are the most critical to ensure efficacy.

The FDA staff notes that topical administration of epinephrine causes constriction of local blood vessels, which could potentially change the absorption of epinephrine in the nasal mucosa and impact systemic plasma concentrations.

Price Action: SPRY shares are down 14.39% at $5.14 on the last check Tuesday.


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Posted In: BiotechNewsHealth CareSmall CapFDAMoversGeneralBriefs